Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics, Inc. - Common Stock (NQ:MRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
Why Shares of Zai Lab Soared This Week
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company. 
Via The Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Mirati Therapeutics: Here's What You Need To Know
 
Via Benzinga
Why Mirati Therapeutics Shares Are Nosediving
Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 4.90% to $41.70 after Citigroup downgraded the stock from Buy to Neutral.  
Via Benzinga
BMO Capital Downgrades Mirati Therapeutics: Here's What You Need To Know
 
Via Benzinga
SKLZ Stock Alert: Will Skillz Shares Get Delisted?
Skillz (SKLZ) stock is worth checking on today as the company received a delisting notice from the New York Stock Exchange. 
Via InvestorPlace
Why Are Chinese EV Stocks NIO, XPEV, LI on Watch Today?
Chinese electric vehicle (EV) stocks are a chief concern among investors today as these shares see mixed trading on Thursday! 
Via InvestorPlace
Why Is ProQR (PRQR) Stock Up 83% Today?
ProQR (PRQR) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (LLY). 
Via InvestorPlace
Why Is Mirati Therapeutics (MRTX) Stock Up Today?
Mirati Therapeutics (MRTX) stock is rising on Thursday as investors react to a special designation from the FDA for adagrasib. 
Via InvestorPlace
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
What 10 Analyst Ratings Have To Say About Mirati Therapeutics
 
Via Benzinga
Where Mirati Therapeutics Stands With Analysts
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
 
Via Benzinga
Tesla To $235? Here Are 10 Other Price Target Changes For Wednesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $305 to $235. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 0.4% to $160.35 in pre-market... 
Via Benzinga
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
Another Competitor For Amgen As FDA Approves Mirati Therapeutics' KRAS Inhibitor For Lung Cancer Setting
 
Via Benzinga
Pinterest, Oracle And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. ACM Research, Inc. (NASDAQ: ACMR) shares jumped 25.9% to $10.98 in... 
Via Benzinga
Nasdaq, S&P 500 Futures Soar Amid Optimistic Expectations Concerning Nov. Inflation: Oracle, Tesla, Pinterest Among Early Movers
The index futures point to a modestly higher opening for the market on Tuesday, although the November consumer price inflation due ahead of the open could sway sentiment either way depending on how the... 
Via Benzinga
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days
The company is still planning a Phase 3 study in non-small cell lung cancer. 
Via Investor's Business Daily
Why Mirati Therapeutics Shares Are Getting Hammered Again Today
Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 12.18% to $43.55 during Thursday's session after multiple analysts downgraded their ratings on the stock and lowered their price... 
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
Via Benzinga
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
 
Via Benzinga
Why Shares of Mirati Therapeutics Fell Wednesday
The company presented phase 2 data from its non-small cell lung cancer therapy. 
Via The Motley Fool
Why Mirati Therapeutics Stock Is Trading Sharply Lower Today
Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 29.32% to $50.55 on continued weakness after the company announced late-breaking results 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.